Literature DB >> 21155039

The role of 18F-FDG PET/CT in the evaluation of gastric cancer recurrence after curative gastrectomy.

Ji Eun Lee1, Sung Pyo Hong, Dae Ho Ahn, Tae Joo Jeon, Min Kyung Kang, Chang Il Kwon, Kwang Hyun Ko, Seong Gyu Hwang, Pil Won Park, Kyu Sung Rim.   

Abstract

PURPOSE: (18)F-fluorodeoxyglucose positron emission tomography/computed tomography ((18)F-FDG PET/CT) scans are frequently performed for the screening or staging of malignant tumors. This study aimed to assess the usefulness of (18)F-FDG PET/CT in detection of gastric cancer recurrence after curative gastrectomy.
MATERIALS AND METHODS: Eighty nine patients who had undergone curative gastrectomy due to gastric cancer and had (18)F-FDG PET/CT and contrast CT scans within 2 weeks for surveillance in asymptomatic patients (n = 11) or to clarify suspected recurrence (n = 78) were consecutively collected and retrospectively analyzed. They had clinical follow-up for at least 12 months after PET/CT and CT scans.
RESULTS: Fifteen of the 89 patients (16.9%) were diagnosed with recurrent gastric cancer in 21 organs. Forty one organs showed an increase in FDG uptake, and only 9 of these organs were diagnosed with recurrent gastric cancer by (18)F-FDG PET/CT. The sensitivity, specificity, positive predictive value, negative predictive value, and diagnostic accuracy of the (18)F-FDG PET/CT were 42.9%, 59.7%, 29.3%, 78.2%, and 57.3%, respectively. On the CT scan, 18 of 21 recurrent gastric cancers were detected, and 7 cases were in agreement with the (18)F-FDG PET/CT. The sensitivity and specificity of the CT scan were 85.8% and 87.3%, respectively, which are superior to the (18)F-FDG PET/CT. When we diagnosed a recurrence based on either (18)F-FDG PET/CT or CT scans, the sensitivity increased to 95.2% and the specificity decreased to 45.6%, when compared with the contrast CT scan alone.
CONCLUSION: (18)F-FDG PET/CT is an insufficient diagnostic method in detection of recurrence after curative gastrectomy, and even less accurate than contrast CT scan alone.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21155039      PMCID: PMC3017712          DOI: 10.3349/ymj.2011.52.1.81

Source DB:  PubMed          Journal:  Yonsei Med J        ISSN: 0513-5796            Impact factor:   2.759


  16 in total

Review 1.  Imaging diagnosis for staging of gastric cancer.

Authors:  C Kuntz; C Herfarth
Journal:  Semin Surg Oncol       Date:  1999-09

2.  Increased F-18 FDG uptake in the stomach.

Authors:  R F Nunez; H W Yeung; H Macapinlac
Journal:  Clin Nucl Med       Date:  1999-04       Impact factor: 7.794

Review 3.  CT and PET in stomach cancer: preoperative staging and monitoring of response to therapy.

Authors:  Joon Seok Lim; Mi Jin Yun; Myeong-Jin Kim; Woo Jin Hyung; Mi-Suk Park; Jin-Young Choi; Tae-Sung Kim; Jong Doo Lee; Sung Hoon Noh; Ki Whang Kim
Journal:  Radiographics       Date:  2006 Jan-Feb       Impact factor: 5.333

4.  Whole-body PET with FDG for the diagnosis of recurrent gastric cancer.

Authors:  T De Potter; P Flamen; E Van Cutsem; F Penninckx; L Filez; G Bormans; A Maes; L Mortelmans
Journal:  Eur J Nucl Med Mol Imaging       Date:  2002-02-23       Impact factor: 9.236

5.  [Roles of F-18 FDG PET or PET/CT for the evaluation of gastrointestinal malignancies].

Authors:  Mijin Yun; Byung-il Kim
Journal:  Korean J Gastroenterol       Date:  2006-12

6.  The role of gastric distention in differentiating recurrent tumor from physiologic uptake in the remnant stomach on 18F-FDG PET.

Authors:  Mijin Yun; Hyun Seok Choi; Eunhye Yoo; Jung Kyun Bong; Young Hoon Ryu; Jong Doo Lee
Journal:  J Nucl Med       Date:  2005-06       Impact factor: 10.057

7.  Incidental PET/CT findings in the cancer patient: how should they be managed?

Authors:  John S Beatty; Hadyn T Williams; Beau A Aldridge; Matthew P Hughes; Viren S Vasudeva; Angela L Gucwa; George S David; D Scott Lind; E James Kruse; James M McLoughlin
Journal:  Surgery       Date:  2009-08       Impact factor: 3.982

8.  Clinical role of 18F-fluorodeoxyglucose positron emission tomography/computed tomography in post-operative follow up of gastric cancer: initial results.

Authors:  Long Sun; Xin-Hui Su; Yong-Song Guan; Wei-Ming Pan; Zuo-Ming Luo; Ji-Hong Wei; Hua Wu
Journal:  World J Gastroenterol       Date:  2008-08-07       Impact factor: 5.742

9.  Clinical value of whole-body FDG-PET for recurrent gastric cancer: a multicenter study.

Authors:  Yuji Nakamoto; Kaori Togashi; Tomohiro Kaneta; Hiroshi Fukuda; Kotaro Nakajima; Kazuhiro Kitajima; Koji Murakami; Hirofumi Fujii; Mitsuo Satake; Ukihide Tateishi; Kazuo Kubota; Michio Senda
Journal:  Jpn J Clin Oncol       Date:  2009-03-05       Impact factor: 3.019

10.  The role of PET/CT in detection of gastric cancer recurrence.

Authors:  Sung Hoon Sim; Yu Jung Kim; Do-Youn Oh; Se-Hoon Lee; Dong-Wan Kim; Won Jun Kang; Seock-Ah Im; Tae-You Kim; Woo Ho Kim; Dae Seog Heo; Yung-Jue Bang
Journal:  BMC Cancer       Date:  2009-03-01       Impact factor: 4.430

View more
  5 in total

Review 1.  Imaging of Gastric Cancer Metabolism Using 18 F-FDG PET/CT.

Authors:  Mijin Yun
Journal:  J Gastric Cancer       Date:  2014-03-31       Impact factor: 3.720

2.  Diagnostic performance of FDG PET/CT for surveillance in asymptomatic gastric cancer patients after curative surgical resection.

Authors:  Jeong Won Lee; Sang Mi Lee; Myoung Won Son; Moon-Soo Lee
Journal:  Eur J Nucl Med Mol Imaging       Date:  2015-11-27       Impact factor: 9.236

3.  The Role of 18F-FDG PET/CT in the Evaluation of Gastric Cancer Recurrence.

Authors:  Hakan Cayvarlı; Recep Bekiş; Tülay Akman; Deniz Altun
Journal:  Mol Imaging Radionucl Ther       Date:  2014-10-05

4.  Prognostic Value of Restaging F-18 Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography to Predict 3-Year Post-Recurrence Survival in Patients with Recurrent Gastric Cancer after Curative Resection.

Authors:  Sung Hoon Kim; Bong Il Song; Hae Won Kim; Kyoung Sook Won; Young Gil Son; Seung Wan Ryu
Journal:  Korean J Radiol       Date:  2020-07       Impact factor: 3.500

5.  Evaluation of Dual Time Point Imaging 18F-FDG PET/CT in Differentiating Malignancy From Benign Gastric Disease.

Authors:  Jing Cui; Panxiong Zhao; Zhentai Ren; Baoping Liu
Journal:  Medicine (Baltimore)       Date:  2015-08       Impact factor: 1.817

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.